Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE REDIDOSE versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE REDIDOSE versus PROMETHAZINE VC PLAIN.
LORATADINE REDIDOSE vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
10 mg orally once daily
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic